Cantargia: Fast Track in IL1-RAP High Patients - Redeye

The fast-track designation from the FDA in metastatic pancreatic cancer confirms Cantargia's strategy of developing nadunolimab in patients high IL1RAP expression levels. Redeye provides a brief comment.

Länk till analysen i sin helhet: https://www.redeye.se/research/1115058/cantargia-fast-track-in-il1-rap-high-patients?utm_source=finwire&utm_medium=RSS